STING1 and neoplasm: Yang et al. explored the role of STING signaling at low dose rates using radium-223 (223Ra), an α-particle emitter with an 11.43 days half-life that targets to bone, in a mouse model with syngeneic tumor cells in the bone marrow (Yang et al., 2024).